This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sansum Diabetes Research Institute Appoints Rem Laan As Executive Director

SANTA BARBARA, Calif., March 18, 2013 /PRNewswire-USNewswire/ -- Sansum Diabetes Research Institute is pleased to announce the appointment of Rem Laan as Executive Director.  He will be responsible for the non-profit organization's strategic planning , operations, major gift development and cultivation of donor relationships.

(Photo: http://photos.prnewswire.com/prnh/20130318/DC78036 )



Mr. Laan has extensive industry experience in the field of diabetes in the U.S. and globally.  He comes to Sansum Diabetes from Roche Diagnostics, where he spent more than ten years in successively responsible positions culminating in his role as Vice President for External Affairs in their North American Diabetes Care business.  Previously, Mr. Laan was Director of Marketing for Disetronic Medical Systems, a Swiss insulin pump manufacturer, for more than four years until it was acquired by Roche.  He recently spent nearly six years with Roche in Mannheim, Germany as a Vice President of Marketing for the Diabetes Care division.  During his tenure with Roche, he participated in developing ACCU-CHEK® 360° View, a blood glucose analysis system, and driving the adoption on a global basis of therapy adjustment based on pattern analysis.  This simple but very effective approach for general practitioners treating patients with type 2 diabetes is the subject of numerous clinical studies, several patents, and is being incorporated by organizations such as the International Diabetes Federation into their guidelines. 

Mr. Laan also led Roche's strategy development and implementation tactics with respect to artificial pancreas development.  Roche Diabetes Care is a $46 billion dollar enterprise and a major force in diabetes research worldwide.  Roche Diabetes Care is the #1 blood glucose meter manufacturer and the #2 insulin pump manufacturer worldwide.



"I am honored and excited to have the opportunity to join a superbly talented, dedicated team and share my expertise with Sansum Diabetes Research Institute, an internationally acclaimed leader in the quest to prevent, treat and ultimately cure diabetes.  Together, we will continue the relentless pursuit of excellence in diabetes care established by Dr. William Sansum nearly 70 years ago."

Mr. Laan's professional background also includes his participation on several key industry advisory boards: Juvenile Diabetes Research Foundation (JDRF) Industry Partner Advisory Panel, American Association of Clinical Endocrinologists (AACE) Corporate Advisory Panel and the ENDO Society Corporate Liaison Board.  He received his bachelor's degree in Economics from Carleton College and MBA from the Tuck School of Business at Dartmouth College.

"This is an important time in the history of Sansum Diabetes Research Institute, as we recognize that our continued growth requires the stewardship of an Executive Director to take our Institute to the next level.  Mr. Laan's leadership will be instrumental in expanding our presence in the global diabetes arena and I look forward to collaborating with him," said Lois  Jovanovic, MD, MACE, Chief Scientific Officer for the Institute.

Ellen Goodstein, President of the Board of Trustees for Sansum Diabetes, stated that, "On behalf of the Board and staff, I am delighted to welcome Mr. Laan to our organization.  He embodies a rare combination of business acumen, the ability to communicate with physicians, scientists and industry professionals and displays extraordinary compassion for those afflicted with diabetes.  He will be a great asset as we expand our efforts to raise sustainable funding for our work." 



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs